A citation-based method for searching scientific literature

Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.
Volker M Lauschke, Lili Milani, Magnus Ingelman-Sundberg. AAPS J 2017
Times Cited: 78



Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.
Mikael Kozyra, Magnus Ingelman-Sundberg, Volker M Lauschke. Genet Med 2017
Times Cited: 142




List of shared articles



Times cited

Technologies for Pharmacogenomics: A Review.
Maaike van der Lee, Marjolein Kriek, Henk-Jan Guchelaar, Jesse J Swen. Genes (Basel) 2020
13

Exome-Wide Analysis of the DiscovEHR Cohort Reveals Novel Candidate Pharmacogenomic Variants for Clinical Pharmacogenomics.
Maria-Theodora Pandi, Marc S Williams, Peter van der Spek, Maria Koromina, George P Patrinos. Genes (Basel) 2020
3

Pharmacogenes (PGx-genes): Current understanding and future directions.
Pramod Katara, Anamika Yadav. Gene 2019
13

Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions.
Magnus Ingelman-Sundberg, Volker M Lauschke. Pharmacogenomics 2018
10

Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions.
Sulev Reisberg, Kristi Krebs, Maarja Lepamets, Mart Kals, Reedik Mägi, Kristjan Metsalu, Volker M Lauschke, Jaak Vilo, Lili Milani. Genet Med 2019
48

Variant discovery using next-generation sequencing and its future role in pharmacogenetics.
Laura E Russell, Ute I Schwarz. Pharmacogenomics 2020
8

Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier.
Yitian Zhou, Carolina Dagli Hernandez, Volker M Lauschke. Br J Cancer 2020
17

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing.
Yitian Zhou, Stefania Koutsilieri, Erik Eliasson, Volker M Lauschke. Basic Clin Pharmacol Toxicol 2022
2

Pharmacogenetics of HIV therapy: challenges for tailoring treatment in genetically complex populations.
Camila de Almeida Velozo, Cynthia Chester Cardoso. Pharmacogenomics 2022
0

Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data.
Yitian Zhou, Kohei Fujikura, Souren Mkrtchian, Volker M Lauschke. Front Pharmacol 2018
42

Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation.
Volker M Lauschke, Magnus Ingelman-Sundberg. NPJ Genom Med 2020
24

Integrating rare genetic variants into pharmacogenetic drug response predictions.
Magnus Ingelman-Sundberg, Souren Mkrtchian, Yitian Zhou, Volker M Lauschke. Hum Genomics 2018
105

Pharmacogenomics in the era of next generation sequencing - from byte to bedside.
Laura E Russell, Yitian Zhou, Ahmed A Almousa, Jasleen K Sodhi, Chukwunonso K Nwabufo, Volker M Lauschke. Drug Metab Rev 2021
11

A novel machine learning-based approach for the computational functional assessment of pharmacogenomic variants.
Maria-Theodora Pandi, Maria Koromina, Iordanis Tsafaridis, Sotirios Patsilinakos, Evangelos Christoforou, Peter J van der Spek, George P Patrinos. Hum Genomics 2021
6

Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.
Volker M Lauschke, Yitian Zhou, Magnus Ingelman-Sundberg. Pharmacol Ther 2019
50

Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response.
Janet Piñero, Abel Gonzalez-Perez, Emre Guney, Joaquim Aguirre-Plans, Ferran Sanz, Baldo Oliva, Laura I Furlong. Front Genet 2018
6

Challenges Related to the Use of Next-Generation Sequencing for the Optimization of Drug Therapy.
Yitian Zhou, Volker M Lauschke. Handb Exp Pharmacol 2022
0

An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Yitian Zhou, Souren Mkrtchian, Masaki Kumondai, Masahiro Hiratsuka, Volker M Lauschke. Pharmacogenomics J 2019
67

Polymorphisms at CYP enzymes, NR1I2 and NR1I3 in association with virologic response to antiretroviral therapy in Brazilian HIV-positive individuals.
Camila de Almeida Velozo, Tailah Bernardo de Almeida, Marcelo Costa Velho Mendes de Azevedo, Isabela Espasandin, Jorge Francisco da Cunha Pinto, Sheila López, Luciana Pizzatti, Amilcar Tanuri, Sabrina da Silva Santos, Marcelo Ribeiro-Alves,[...]. Pharmacogenomics J 2022
1

Challenges and opportunities associated with rare-variant pharmacogenomics.
Yitian Zhou, Roman Tremmel, Elke Schaeffeler, Matthias Schwab, Volker M Lauschke. Trends Pharmacol Sci 2022
1

Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
Volker M Lauschke, Magnus Ingelman-Sundberg. Eur J Pharm Sci 2019
29

Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment.
Leyre Pernaute-Lau, Ayola Akim Adegnika, Yitian Zhou, Jeannot F Zinsou, Jose Pedro Gil, Sanjeev Krishna, Peter G Kremsner, Volker M Lauschke, Thirumalaisamy P Velavan. Antimicrob Agents Chemother 2021
6

Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews.
Yitian Zhou, Volker M Lauschke. J Med Genet 2018
18

Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability.
Yitian Zhou, Volker M Lauschke. Clin Pharmacol Ther 2021
10

Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records.
Tõnis Tasa, Kristi Krebs, Mart Kals, Reedik Mägi, Volker M Lauschke, Toomas Haller, Tarmo Puurand, Maido Remm, Tõnu Esko, Andres Metspalu,[...]. Eur J Hum Genet 2019
19


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy